{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:44:47Z","timestamp":1787870687457,"version":"build-2784847793"},"publisher-location":"Cham","reference-count":25,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031598142","type":"print"},{"value":"9783031598159","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-59815-9_31","type":"book-chapter","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T22:01:55Z","timestamp":1723154515000},"page":"459-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Cytokine Storm of Multicentric Castleman Disease"],"prefix":"10.1007","author":[{"given":"David C.","family":"Fajgenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"31_CR1","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June C. Cytokine storm. NEJM. 2020;383:2255\u201373.","journal-title":"NEJM"},{"key":"31_CR2","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1182\/blood-2013-08-519959","volume":"122","author":"MN Polizzotto","year":"2013","unstructured":"Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2013;122:4189\u201398.","journal-title":"Blood"},{"key":"31_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","volume":"135","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135:1353\u201364.","journal-title":"Blood"},{"issue":"21","key":"31_CR4","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMcpc2115849","volume":"386","author":"DC Fajgenbaum","year":"2022","unstructured":"Fajgenbaum DC, Goiffon RJ, Soumerai JD, Harris CK. Case 16-2022: a 55-year-old man with fevers, night sweats, and a mediastinal mass. N Engl J Med. 2022;386(21):2036\u201348.","journal-title":"N Engl J Med"},{"issue":"20","key":"31_CR5","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115\u201324.","journal-title":"Blood"},{"issue":"9","key":"31_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1046\/j.1440-1827.2001.01266.x","volume":"51","author":"T Suda","year":"2001","unstructured":"Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS- associated multicentric Castleman\u2019s disease. Pathol Int. 2001;51(9):671\u20139.","journal-title":"Pathol Int"},{"issue":"7","key":"31_CR7","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1182\/blood.V97.7.2130","volume":"97","author":"MQ Du","year":"2001","unstructured":"Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma- associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lympho- proliferative disorders. Blood. 2001;97(7):2130\u20136.","journal-title":"Blood"},{"key":"31_CR8","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood.2019004602","volume":"135","author":"R Ramaswami","year":"2020","unstructured":"Ramaswami R, Lurain K, Peer CJ, et al. Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2020;135:2316\u20139.","journal-title":"Blood"},{"key":"31_CR9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/bjh.12386","volume":"162","author":"D Chellapandian","year":"2013","unstructured":"Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162:376\u201382.","journal-title":"Br J Haematol"},{"key":"31_CR10","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2016-10-747477","volume":"129","author":"AD Pria","year":"2017","unstructured":"Pria AD, Pinato D, Roe J, Naresh K, Nelson M, Bower M. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. Blood. 2017;129:2143\u20137.","journal-title":"Blood"},{"issue":"8","key":"31_CR11","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"N Nishimoto","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor anti-body treatment of multicentric Castleman disease. Blood. 2005;106(8):2627\u201332.","journal-title":"Blood"},{"issue":"23","key":"31_CR12","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","volume":"28","author":"F van Rhee","year":"2010","unstructured":"van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 mono- clonal antibody, for Castleman\u2019s disease. J Clin Oncol. 2010;28(23):3701\u20138.","journal-title":"J Clin Oncol"},{"key":"31_CR13","first-page":"37","volume":"166","author":"SJ Brandt","year":"1990","unstructured":"Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Retroviral-mediated transfer of interleukin-6 into hematopoietic cells of mice results in a syndrome resembling castle- man\u2019s disease. Curr Top Microbiol Immunol. 1990;166:37\u201341.","journal-title":"Curr Top Microbiol Immunol"},{"key":"31_CR14","first-page":"305","volume":"30","author":"P Rieu","year":"2000","unstructured":"Rieu P, No\u00ebl LH, Droz D, et al. Glomerular involvement in lymphoproliferative disorders with hyperproduction of cytokines (Castleman, POEMS). Adv Nephrol Necker Hosp. 2000;30:305\u201331.","journal-title":"Adv Nephrol Necker Hosp"},{"issue":"9","key":"31_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","volume":"15","author":"F van Rhee","year":"2014","unstructured":"van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966\u201374.","journal-title":"Lancet Oncol"},{"key":"31_CR16","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1172\/JCI126091","volume":"130","author":"DC Fajgenbaum","year":"2019","unstructured":"Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade- refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019;130:4451\u201363.","journal-title":"J Clin Invest"},{"issue":"22","key":"31_CR17","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2018-05-848671","volume":"132","author":"DC Fajgenbaum","year":"2018","unstructured":"Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood. 2018;132(22):2323\u201330.","journal-title":"Blood"},{"issue":"6","key":"31_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218660","volume":"14","author":"CS Nabel","year":"2019","unstructured":"Nabel CS, Sameroff S, Shilling D, et al. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS One. 2019;14(6):e0218660.","journal-title":"PLoS One"},{"issue":"4","key":"31_CR19","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","volume":"3","author":"AY Liu","year":"2016","unstructured":"Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman\u2019s disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163\u201375.","journal-title":"Lancet Haematol"},{"key":"31_CR20","first-page":"293","volume":"142","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A. Castleman disease. Cancer Treat Res. 2008;142:293\u2013330.","journal-title":"Cancer Treat Res"},{"issue":"18","key":"31_CR21","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1200\/JCO.2010.34.1909","volume":"29","author":"M Bower","year":"2011","unstructured":"Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman\u2019s disease. J Clin Oncol. 2011;29(18):2481\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"31_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bjh.15019","volume":"180","author":"E Oksenhendler","year":"2018","unstructured":"Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180(2):206\u201316.","journal-title":"Br J Haematol"},{"issue":"19","key":"31_CR23","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","volume":"21","author":"C Casper","year":"2015","unstructured":"Casper C, Chaturvedi S, Munshi N, et al. Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of Siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease. Clin Cancer Res. 2015;21(19):4294\u2013304.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"31_CR24","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959\u201364.","journal-title":"Blood"},{"issue":"17","key":"31_CR25","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1182\/bloodadvances.2020004016","volume":"5","author":"SK Pierson","year":"2021","unstructured":"Pierson SK, Shenoy S, Oromendia AB, Gorzewski AM, Langan Pai RA, Nabel CS, Ruth JR, Parente SAT, Arenas DJ, Guilfoyle M, Reddy M, Weinblatt M, Shadick N, Bower M, Pria AD, Masaki Y, Katz L, Mezey J, Beineke P, Lee D, Tendler C, Kambayashi T, Foss\u00e5 A, van Rhee F, Fajgenbaum DC. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021;5(17):3445\u201356.","journal-title":"Blood Adv"}],"container-title":["Advances in Experimental Medicine and Biology","Cytokine Storm Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-59815-9_31","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T22:06:39Z","timestamp":1723154799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-59815-9_31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031598142","9783031598159"],"references-count":25,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-59815-9_31","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"9 August 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}